Uterine sarcomas are rare tumors with unpredictable prognosis. They ar
e treated similarly to endometrial cancers. Little is known of epidemi
ologic risk factors for or molecular alterations in sarcomas. Because
of their rarity, uterine sarcomas are not suitable for screening. Chem
oprevention studies might target those at risk for a second neoplasm.